Led by GT Securities investment banker Marius Sava, GT Securities’ healthcare and life sciences specialty practice focuses on M&A advisory for the mid-market (US$5-$250 million). We advise on numerous buy and sell side mandates for domestic and cross-border transactions involving small to large public corporations as well as owner managed businesses.
Sectors in which we have successfully transacted include:
- Contract research/development/manufacturing services
- Medical devices
- Professional/consumer health
- Life sciences research/lab/POC instruments and consumables
Below are some representative clients:
GT Securities advised NDG Holdings, a child-friendly, South Central U.S.-based pediatric services company, through its first round of institutional financing with Atlanta – based private equity firm EDG Partners.
Through its affiliate management consultancy Growthink, advised the CEO of Good Samaritan, one of the largest hospitals in Southern California (1,300 employees, 450 nurses, and 625 medical staff) as to strategic and growth alternatives. 6-Month Assignment.
Growthink, GT Securities' affiliated management consultancy, advised McKesson’s (NYSE: MCK) in evaluating the customer and market demand and competitive landscape for a new alternative drug delivery platform and technology offering.
Growthink, GT Securities' affiliated management consultancy, advised M3 Medical - one of Ireland and the UK's largest privately owned medical device distributors - on the development of a new product development platform and its related capital formation strategy. 3-Month assignment.
GT Securities advised Ometric, a Sequoia Capital backed industrial process analytical technology company, through their sale to Halliburton (NYSE:HAL) for an eight figure sum.
Through its affiliate network, GT Securities advised Planet Fitness, through its acquisition by private equity firms Exaltare Capital Partners LLC and Brightwood Capital Advisors LLC.
GT Securities advised Research Scientists, a contract research organization, on its sale to Research Pharmaceutical Services, a large pharmaceuticals contract research solutions provider, for $7,500,000.
GT Securities advised Thrombovision, a provider of biomedical research and development services, on its investor promotion process and introduced Thrombovision to private equity firm National Healthcare Services, who led a $4 million Series A convertible preferred stock financing into the company.